Literature DB >> 21757280

Osteonecrosis after administration of intravitreous bevacizumab.

Renato Nicolás Hopp1, Juliana Pucci, Alan Roger Santos-Silva, Jacks Jorge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21757280     DOI： 10.1016/j.joms.2011.02.104

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN： 0278-2391            Impact factor:   1.895


× No keyword cloud information.
  10 in total

Review 1.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

2.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Authors:  Jason Fangusaro; Sridharan Gururangan; Regina I Jakacki; Sue C Kaste; Stewart Goldman; Ian F Pollack; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

3.  Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?

Authors:  Hiroaki Shimamoto; Tristan R Grogan; Tomomi Tsujimoto; Naoya Kakimoto; Shumei Murakami; David Elashoff; Tara L Aghaloo; Sotirios Tetradis
Journal:  Dentomaxillofac Radiol       Date:  2017-12-15       Impact factor: 2.419

4.  A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians.

Authors:  Sung Ok Hong; Chae-Yoon Lee; Junho Jung; Deog-Yoon Kim; Christian Walter; Yong-Dae Kwon
Journal:  Clin Oral Investig       Date:  2016-10-22       Impact factor: 3.573

5.  Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice.

Authors:  Yuri Akita; Shinichiro Kuroshima; Kazunori Nakajima; Hiroki Hayano; Riho Kanai; Muneteru Sasaki; Takashi Sawase
Journal:  J Bone Miner Metab       Date:  2017-10-17       Impact factor: 2.626

6.  Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors:  Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal:  BMJ Case Rep       Date:  2012-10-22

7.  Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.

Authors:  Daria Pakosch; Dimitrios Papadimas; Johanna Munding; Darafsch Kawa; Marcus Stephan Kriwalsky
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

8.  Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges.

Authors:  Morten Schiodt; Cecilia Larsson Wexell; Bente Brokstad Herlofson; Karen Marie Giltvedt; Sven Erik Norholt; Vera Ehrenstein
Journal:  Clin Epidemiol       Date:  2015-01-30       Impact factor: 4.790

Review 9.  Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature.

Authors:  Kununya Pimolbutr; Stephen Porter; Stefano Fedele
Journal:  Biomed Res Int       Date:  2018-04-23       Impact factor: 3.411

Review 10.  Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology.

Authors:  Antonio Fabrizio Nifosì; Mariateresa Zuccarello; Lorenzo Nifosì; Vanessa Hervas Saus; Gianfilippo Nifosì
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2019-02-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.